• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Crude Oil Down 1%; Charles Schwab Sales Top Estimates

    4/15/24 12:02:33 PM ET
    $LGVN
    $MRNS
    $NMRA
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LGVN alert in real time by email

    U.S. stocks traded higher midway through trading, with the Dow Jones index gaining more than 100 points on Monday.

    The Dow traded up 0.35% to 38,114.61 while the NASDAQ rose 0.07% to 16,187.02. The S&P 500 also rose, gaining, 0.26% to 5,136.94.

    Check This Out: Best Buy, Box And 2 Other Stocks Insiders Are Selling

     

    Leading and Lagging Sectors

     

    Health care shares jumped by 0.7% on Friday.

    In trading on Friday, real estate shares fell by 1.1%.

     

    Top Headline

     

    Charles Schwab Corporation (NYSE:SCHW) reported better-than-expected first-quarter earnings on Monday.

    Charles Schwab reported a first-quarter 2024 adjusted net income decline of 17% Y/Y to $1.469 billion. Adjusted EPS fell 20% Y/Y to 74 cents, which came in line with the consensus. Revenue fell 7% to $4.74 billion, marginally beating the consensus of $4.71 billion.

     

    Equities Trading UP

     

    Soligenix, Inc. (NASDAQ:SNGX) shares shot up 49% to $0.5802 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA.

    Shares of Longeveron Inc. (NASDAQ:LGVN) got a boost, surging 52% to $2.5650 following insider buys from multiple company executives.

    Snap One Holdings Corp. (NASDAQ:SNPO) shares were also up, gaining 30% to $10.61 after the company announced that it will be acquired by Resideo Technologies.

     

    Equities Trading DOWN

     

    Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) shares dropped 79% to $1.5792 after the company provided an update on the Phase 3 RAISE trial and reported preliminary first-quarter financial results.

    Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) were down 14% to $11.67 after the FDA placed a clinical hold on the company's Phase 1 NMRA-266 study.

    Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was down, falling 10% to $42.46 after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms.

    Also Check This Out: Wall Street's Most Accurate Analysts' Views On 3 Tech Stocks With Over 4% Dividend Yields

     

    Commodities

     

    In commodity news, oil traded down 1.3% to $84.55 while gold traded down 0.5% at $2,362.00.

    Silver traded up 0.8% to $28.55 on Friday, while copper rose 1.7% to $4.3315.

     

    Euro zone

     

    European shares were mostly higher today. The eurozone’s STOXX 600 rose 0.06%, London’s FTSE 100 fell 0.48% while Spain’s IBEX 35 Index fell 0.11% The German DAX gained 0.39% French CAC 40 climbed 0.31% while Italy’s FTSE MIB Index jumped 0.45%.

    Industrial production in the eurozone increased by 0.8% month-over-month in February.

     

    Asia Pacific Markets

     

    Asian markets closed mostly lower on Monday, with Japan’s Nikkei 225 falling 0.74%, Hong Kong’s Hang Seng Index dropping 0.72%, China’s Shanghai Composite gaining 1.26% and India’s S&P BSE Sensex dipping 1.14%.

    Indian merchandise trade deficit shrank to $15.6 billion in March versus a year-ago gap of $18.1 billion, while wholesale prices rose by 0.53% year-over-year in March versus a 0.20% gain in the prior month.

     

    Economics

     

    The NY Empire State Manufacturing Index climbed to -14.3 in April versus prior month’s reading of -20.9.

    Retail sales increased 0.7% month-over-month in March following a revised 0.9% rise in February.

    The NAHB/Wells Fargo Housing Market Index in came in unchanged at 51.0 in April.

    Total business inventories increased by 0.4% month-over-month in February, versus market expectations of a 0.3% rise.

    Now Read This: Bitcoin Surpasses $66,000; Core Emerges As Top Gainer

    Get the next $LGVN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LGVN
    $MRNS
    $NMRA
    $RARE

    CompanyDatePrice TargetRatingAnalyst
    Neumora Therapeutics Inc.
    $NMRA
    1/12/2026$8.00Outperform
    Leerink Partners
    Charles Schwab Corporation
    $SCHW
    12/11/2025$119.00Buy
    UBS
    Neumora Therapeutics Inc.
    $NMRA
    12/1/2025$7.00Sector Perform → Outperform
    RBC Capital Mkts
    Neumora Therapeutics Inc.
    $NMRA
    10/27/2025$14.00Neutral → Buy
    Guggenheim
    Ultragenyx Pharmaceutical Inc.
    $RARE
    10/20/2025$65.00Overweight
    Wells Fargo
    Charles Schwab Corporation
    $SCHW
    10/3/2025$110.00Outperform
    BMO Capital Markets
    Neumora Therapeutics Inc.
    $NMRA
    9/16/2025Neutral → Underweight
    Analyst
    Ultragenyx Pharmaceutical Inc.
    $RARE
    7/28/2025$80.00Buy
    H.C. Wainwright
    More analyst ratings

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Co-Chairman Schwab Charles R. gifted 60,000 shares and sold $16,868,627 worth of shares (158,613 units at $106.35) (SEC Form 4)

    4 - SCHWAB CHARLES CORP (0000316709) (Issuer)

    2/11/26 9:18:24 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    Co-Chairman Bettinger Walter W exercised 67,514 shares at a strike of $42.99 and sold $7,038,476 worth of shares (67,514 units at $104.25) (SEC Form 4)

    4 - SCHWAB CHARLES CORP (0000316709) (Issuer)

    2/10/26 7:49:11 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    Director Dodds Christopher V exercised 11,825 shares at a strike of $64.03 and sold $1,236,314 worth of shares (11,825 units at $104.55) (SEC Form 4)

    4 - SCHWAB CHARLES CORP (0000316709) (Issuer)

    2/10/26 7:32:11 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Leerink Partners initiated coverage on Neumora Therapeutics with a new price target

    Leerink Partners initiated coverage of Neumora Therapeutics with a rating of Outperform and set a new price target of $8.00

    1/12/26 8:18:29 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    UBS resumed coverage on Charles Schwab with a new price target

    UBS resumed coverage of Charles Schwab with a rating of Buy and set a new price target of $119.00

    12/11/25 9:06:22 AM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    Neumora Therapeutics upgraded by RBC Capital Mkts with a new price target

    RBC Capital Mkts upgraded Neumora Therapeutics from Sector Perform to Outperform and set a new price target of $7.00

    12/1/25 8:13:43 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    2025 total revenue of $673 million,Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a strategic restructuring plan to significantly reduce and focus expenses and headcount, reiterate path to profitability in 2027 2026 catalysts include two potential approvals and expected pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and

    2/12/26 4:01:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix Details Recent Progress and Upcoming Milestones

    PRINCETON, N.J., Feb. 12, 2026 /PRNewswire/ -- Soligenix, Inc. (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, today issued an update letter from its President and Chief Executive Officer, Dr. Christopher J. Schaber.  The content of this letter is provided below. Dear Friends and Shareholders, I would like to start by thanking you for your continued support, and by wishing you and your families a Happy New Year. With 2026 being an imp

    2/12/26 7:30:00 AM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schwab Trading Activity Index™: STAX Score Sees Highest Reading Since February 2025

    Schwab clients were net buyers of equities in January, with a net buying surge in the Information Technology sector The Schwab Trading Activity Index™ (STAX) increased to 49.96 in January, up from its score of 48.48 in December. The only index of its kind, the STAX is a proprietary, behavior-based index that analyzes retail investor stock positions and trading activity from Schwab's millions of client accounts to illuminate what investors were actually doing and how they were positioned in the markets each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260209219779/en/ "After a one-month backtrack in December, Schwab cl

    2/9/26 12:30:00 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    $LGVN
    $MRNS
    $NMRA
    $RARE
    SEC Filings

    View All

    Ultragenyx Pharmaceutical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Costs Associated with Exit or Disposal Activities, Financial Statements and Exhibits

    8-K - Ultragenyx Pharmaceutical Inc. (0001515673) (Filer)

    2/12/26 4:11:52 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Soligenix Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - SOLIGENIX, INC. (0000812796) (Filer)

    2/12/26 4:05:19 PM ET
    $SNGX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Neumora Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Neumora Therapeutics, Inc. (0001885522) (Filer)

    2/11/26 7:00:26 AM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Burow Kristina bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:22:24 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Arch Venture Partners Xii, Llc bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:21:13 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Large owner Arch Venture Partners X, Llc bought $4,999,977 worth of shares (1,915,700 units at $2.61) (SEC Form 4)

    4 - Neumora Therapeutics, Inc. (0001885522) (Issuer)

    10/29/25 7:19:14 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Leadership Updates

    Live Leadership Updates

    View All

    Charles Schwab Corporation Announces Executive Transitions

    The Charles Schwab Corporation (NYSE:SCHW) today announced several executive transitions, including two planned retirements and organizational updates. Charles Schwab Bank Leadership Transition Paul Woolway, CEO of Charles Schwab Bank, will retire on July 1, 2026, after more than 16 years with the company. Tyler Woulfe, Managing Director, Banking & Trust Services, will succeed Woolway as President and CEO of Charles Schwab Bank, effective July 1, 2026, and will report to Neesha Hathi, Managing Director, Wealth Advisory and Banking Services. Internal Audit Leadership Transition Mitch Mantua, General Auditor, also retires on July 1, 2026, after a decade of service. Jessica Bramhall, M

    1/29/26 4:15:00 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    George Paletta, Jr., MD, MBA, Internationally Acclaimed Entrepreneur, Investor and Surgeon, Elected to Longeveron® Board of Directors

    MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapies for life-threatening, rare pediatric and chronic aging-related conditions, today announced that George Paletta, Jr., MD, MBA, has been elected to the Longeveron Board of Directors. Dr. Paletta is a nationally and internationally recognized orthopedic surgeon and the head team doctor for the St. Louis Cardinals. Dr. Paletta is a developer of ambulatory surgical centers (ASCs), and has participated in the selling of two ASCs with deal values totaling almost $1 billion. "I am delighted to welcome George, and his tremendous experience as a physician, inv

    10/1/25 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx Appoints Eric Olson as Chief Business Officer and Executive Vice President

    NOVATO, Calif., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) today announced the appointment of Eric Olson as chief business officer (CBO) and executive vice president effective September 22, 2025, following the planned retirement of Thomas Kassberg. Mr. Olson will be responsible for leading the company's business development, corporate development and alliance management functions. "We thank Tom for his 14 years of impactful contributions to Ultragenyx, including transformative business deals that helped build the largest clinical pipeline in rare disease; expanded our reach to patients with fatty acid oxidation diseases, X-linked hypophosphatemia, o

    9/30/25 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Financials

    Live finance-specific insights

    View All

    Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

    2025 total revenue of $673 million,Crysvita® revenue of $481 million and Dojolvi® revenue of $96 million 2026 total revenue from current products expected to be between $730 million to $760 million Initiated a strategic restructuring plan to significantly reduce and focus expenses and headcount, reiterate path to profitability in 2027 2026 catalysts include two potential approvals and expected pivotal Phase 3 data from the GTX-102 Phase 3 Aspire study for Angelman syndrome NOVATO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and

    2/12/26 4:01:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update

    NOVATO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, February 12, 2026, to discuss its financial results and corporate update for the quarter and the year ending December 31, 2025. The live and replayed webcast of the call will be available through the company's website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months. About Ultragenyx Pharmaceutical Inc.Ultragenyx

    2/5/26 4:05:00 PM ET
    $RARE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Schwab Declares 19% Increase in Quarterly Common Stock Dividend and Declares Preferred Stock Dividends

    The Board of Directors of The Charles Schwab Corporation at its meeting today declared a 5 cent, or 19%, increase in the regular quarterly cash dividend to $0.32 per common share. The dividend is payable February 27, 2026 to stockholders of record as of the close of business on February 13, 2026. Co-Chairman Walt Bettinger commented, "This dividend increase reflects the Board's confidence in our ability to continue to drive profitable growth through-the-cycle as we advance our ‘Through Clients' Eyes' strategy." In addition, the Board of Directors also declared dividends on the following series of outstanding preferred stock, payable March 2, 2026 to stockholders of record as of the clos

    1/29/26 4:18:00 PM ET
    $SCHW
    Investment Bankers/Brokers/Service
    Finance

    $LGVN
    $MRNS
    $NMRA
    $RARE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Neumora Therapeutics Inc.

    SC 13D/A - Neumora Therapeutics, Inc. (0001885522) (Subject)

    11/22/24 5:33:43 PM ET
    $NMRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Marinus Pharmaceuticals Inc.

    SC 13G/A - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/15/24 10:35:20 AM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Marinus Pharmaceuticals Inc.

    SC 13G - MARINUS PHARMACEUTICALS, INC. (0001267813) (Subject)

    11/14/24 6:39:04 PM ET
    $MRNS
    Biotechnology: Pharmaceutical Preparations
    Health Care